Amicogen, Inc.

KOSDAQ 092040.KQ

Amicogen, Inc. Current Liabilities for the year ending December 31, 2023: USD 134.31 M

Amicogen, Inc. Current Liabilities is USD 134.31 M for the year ending December 31, 2023, a -17.14% change year over year. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.
  • Amicogen, Inc. Current Liabilities for the year ending December 31, 2022 was USD 162.08 M, a 20.68% change year over year.
  • Amicogen, Inc. Current Liabilities for the year ending December 31, 2021 was USD 134.31 M, a 106.43% change year over year.
  • Amicogen, Inc. Current Liabilities for the year ending December 31, 2020 was USD 65.07 M, a 15.18% change year over year.
  • Amicogen, Inc. Current Liabilities for the year ending December 31, 2019 was USD 56.49 M, a 18.42% change year over year.
Key data
Date Current Liabilities Total Non-Current Liabilities Shareholders' Equity Long-Term Debt
Market news
Loading...
SV Wall Street
KOSDAQ: 092040.KQ

Amicogen, Inc.

Description

Amicogen, Inc. operates as an industrial biotechnology company in South Korea and internationally. The company offers specialty enzymes, including CX, SP, etc. for pharmaceutical, food, chemical, and energy industries. It also provides new bio-ingredients, such as N-acetylglucosamine for skin moisturizing and joint health; pinitol/D-chiro-inositol; collagen peptide and collagen tripeptide for skin and health; chitoslim and chitosan oligosaccharides; and lactic acid bacteria, as well as fucoxanthin, curezyme, food enzyme, and bamboo salt. In addition, the company offers K-nutra, a healthcare brand; and KeyClean, a disinfectant brand. Further, it provides protein purification resins. The company was founded in 2000 and is headquartered in Jinju-si, South Korea.

Similar companies

196170.KQ

ALTEOGEN Inc.

USD 240.05

-5.25%

039130.KS

Hanatour Service Inc.

USD 36.84

-3.71%

078340.KQ

Com2uS Corporation

USD 31.73

-1.83%

StockViz Staff

February 4, 2025

Any question? Send us an email